Ajanta Pharma
Ajanta Pharma Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
India business is expected to grow at mid-teens (around 16-18%) in FY27. Ajanta Pharma expects high-teens revenue growth for FY27, approximately 16%-18%.
From Ajanta Pharma's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business is expected to grow at mid-teens (around 16-18%) in FY27.
- Asia business is guided for high double-digit growth next year, recovering from logistics delays.
- Africa business targeted for high double-digit growth.
- US generics business to grow at mid-single digit in the coming year after strong 49% growth in FY26.
- Chronic therapy areas (around 50% of combined Asia and Africa branded generics market) will remain a focus.
- Gynaecology segment in India showing encouraging progress, expected to contribute meaningfully over next 2-3 years.
- Nephrology segment in India developing slowly, positive signs but longer gestation.
- Overall company targeting revenue growth in the high teens (~16-18%) for FY27.
- Growth driven by volume increase, price growth, and new product launches (new products contributed 4.7% growth in FY26).
- Addition of medical representatives planned to support growth across therapies and geographies.
Profitability & Margins
See what Ajanta Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure for FY 2026 stood at Rs. 330 crores, in line with guidance.
- Ajanta Pharma is embarking upon a new capex cycle to meet continued growth requirements.
- For FY 2027, capex is expected to increase to around Rs. 400 crores.
- Of this, Rs. 150 crores is allocated for maintenance, and the balance for new capacity expansion.
- The company is investing in product range expansion and addition of medical representatives across geographies.
- Increased filing activities are planned, leading to a slight rise in R&D costs.
- Strategic investments also include a focus on digitalization and AI to improve efficiencies, but no significant near-term impact on R&D expenses is expected.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ajanta Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Ajanta Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.4K Cr, net profit ₹267 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ajanta Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenteral's (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Ajanta Pharma Q4 FY26 results?
India business is expected to grow at mid-teens (around 16-18%) in FY27. Ajanta Pharma expects high-teens revenue growth for FY27, approximately 16%-18%.
What is Ajanta Pharma share price analysis?
Ajanta Pharma currently shows a below-average growth signal. The stock trades at a P/E of 40.1 with a market cap of ₹45,483 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ajanta Pharma planning capital expenditure?
Capital expenditure for FY 2026 stood at Rs.
Keep Ajanta Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.